1200 Pharma
Accelerate drug discovery with precision
Pasadena, CA, US
A clinical-stage pharmaceutical company developing novel drug formulations for oncology indications using its proprietary MITO technology platform to target the mitochondria of cancer cells.
How We Help
Problem Statement
Developing treatments for rare and hard-to-treat cancers by selectively delivering therapeutic compounds to the mitochondria of cancer cells.
Core Technology
MITO technology platform
Key Differentiators
Proprietary MITO technology platform for selective drug delivery to cancer cell mitochondria; Reformulates existing drugs for new oncology indications
Clinical Focus
Oncology
Company Info
- Business Model
- Hybrid
- Founded
- 2019
- Total Funding
- 14,080,000
- Website
- 1200pharma.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Grounded in rigorous science from Caltech and UCLA with preclinical and clinical data on multiple oncology programs including KRASG12C, ERK1/2, and PRMT5 inhibitors
MedStartr Index Score
?What do you think of 1200 Pharma?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.